Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Biotechnology

UFOVAX

Ji Li

Jiang Zhu

The founding team at UFOVAX has experience in a variety of industries, including pharmaceuticals, technology, and healthcare. They have a wealth of knowledge in areas such as mergers and acquisitions, management, and product development. This team also has a strong educational background, with degrees from top universities in fields such as organic chemistry and biology.

Founding Team

About

Team members

Other teams at UFOVAX

Board of Directors

CEO and Executive Team